Combination of adenovirus-mediated thymidine kinase gene therapy with cytotoxic chemotherapy in bladder cancer in vitro

Seminars in Urologic Oncology

Volumn 21, Issue 3, 2003, Pages 197-205

  Freund, C T F ^a   Tong, X W ^b   Rowley, D ^c   Engehausen, D ^d   Frolov, A ^a   Kieback, D G ^b   Lerner, Seth P ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Bladder cancer; Chemotherapy; Gene therapy; Thymidine kinase

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; GANCICLOVIR; METHOTREXATE; MITOMYCIN C; THYMIDINE KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; HUMAN; HUMAN CELL; MONOTHERAPY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VIRAL GENE THERAPY;

ADENOVIRUSES, HUMAN; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ENZYME INHIBITORS; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; HUMANS; METHOTREXATE; MITOMYCIN; RECOMBINANT FUSION PROTEINS; SIMPLEXVIRUS; THYMIDINE KINASE; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 0038339601     PISSN: 10810943     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Malkowicz SB. Intravesical therapy for superficial bladder cancer. Semin Urol Oncol 2000;18:280-8.
2. Edelman MJ. New approaches to treatment of metastatic bladder cancer. Curr Oncol Rep 2000;2:379-85.
3. Block T. Chemotherapy of bladder carcinoma. Current status and trends. Urologe A 1994;33:557-67.
4. Witjes JA, et al. Toxicity and results of MVAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced urothelial carcinoma. Eur Urol 1997;31:414-9.
5. Tong XW, et al. Adenovirus-mediated thymidine kinase gene transduction in human epithelial ovarian cancer cell lines followed by exposure to ganciclovir. Anticancer Res 1996;16:1611-7.
6. Deonarain MP, Spooner RA, Epenetos AA. Genetic delivery of enzymes for cancer therapy. Gene Ther 1995;2:235-44.
7. Moolten FL. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther 1994;1:279-87.
8. Balzarini J, Bohman C, De Clercq E. Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2. J Biol Chem 1993;268:6332-7.
9. McNeish IA, et al. Herpes simplex virus thymidine kinase/ganciclovir-induced cell death is enhanced by co-expression of caspase-3 in ovarian carcinoma cells. Cancer Gene Ther 2001;8:308-19.
10. Freund CTF, et al. Adenovirus-mediated suicide gene therapy for bladder cancer: comparison of the cytomegalovirus- and rous sarcoma virus promoter. Anticancer Res 2000;20:2811-6.
11. Sutton MA, et al. Adenovirus-mediated suicide gene therapy for experimental bladder cancer. Urology 1997;49:173-80.
12. Sutton MA, et al. In vivo adenovirus-mediated suicide gene therapy of orthotopic bladder cancer. Mol Ther 2000;2:211-7.
13. Li Y, et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 1999;59:325-30.
14. Li D, et al. Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer. Clin Cancer Res 1999;5:4175-81.
15. Tanaka T, et al. Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res 1996;56:1341-5.
16. Kaneko S, et al. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res 1995; 55:5283-7.
17. Chen L, et al. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J Clin Invest 1995;96:2775-82.
18. Bass C, et al. Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo. Cancer Gene Ther 1995;2:97-104.
19. Sterman DH, et al. A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma. Cancer Gene Ther 2000;7:1511-8.
20. Balis FM, Holcenberg JS, Poplack DG. Combination chemotherapy. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia: Lippincott-Raven; 1997, p. 216-17.
21. Witjes JA, Mungan NA, Debruyne FM. Management of superficial bladder cancer with intravesical chemotherapy: an update. Urology 2000;56:19-21.
22. Schultz-Lampel D, Lampel A. Neo-adjuvant and adjuvant treatment of locally invasive bladder cancer. Curr Opin Urol 1999;9:419-24.
23. Pariente JL, et al. Place of chemotherapy in the treatment of invasive bladder tumors. Prog Urol 1999;9:219-24.
24. Chen SH, et al. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 1994;91:3054-7.
25. Graham FL, Prevec L. Manipulation of adenovirus vectors. In: Murray EJ, editor. Methods in molecular biology: gene transfer and expression protocols. Clifton, NY: The Humana Press Inc; 1991, p. 109-128.
26. Carmichael J, et al. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment and chemosensitivity testing. Cancer Res 1987;47:936-42.
27. Seraphim LA, et al. In vitro study of the interaction of doxorubicin, thiotepa, and mitomycin-C, agents used for intravesical chemotherapy of superficial bladder cancer. J Urol 1991;145:613-7.
28. Watts PL, et al. Sensitivity of cell lines to mitomycin C. Br J Urol 1996;77:363-6.
29. Mosmann T. Rapid colometric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
30. Scudiero DA, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other cell lines. Cancer Res 1988;48:4827-33.
31. Tomicic MT, et al. DNA polymerase beta mediates protection of mammalian cells against ganciclovir-induced cytotoxicity and DNA breakage. Cancer Res 2001;61:7399-403.
32. Jia L, Yu L, Zhu S. Functional status of p53 and chemosensitivity of colon cancer cell lines. Zhonghua Zhong Liu Za Zhi 2000;22:389-90.
33. Serafin AM, Binder AB, Bohm L. Chemosensitivity of prostatic tumour cell lines under conditions of G2 block abrogation. Urol Res 2001;29:221-7.
34. Schmidt M, Fan Z. Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells. Oncogene 2001; 20:6164-71.
35. Reedijk J, Lohman PH. Cisplatin: synthesis, antitumour activity and mechanism of action. Pharm Weekbl Sci 1985;7:173-80.
36. Calvert H, Judson I, van der Vijgh WJ. Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity. Cancer Surv 1993;17:189-217.
37. Hall AG, Tilby MJ. Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev 1992;6:163-73.
38. Verweij J, Pinedo HM. Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs 1990;1:5-13.
39. Cummings J, et al. Enzymology of mitomycin C metabolic activation in tumour tissue: implications for enzyme-directed bioreductive drug development. Biochem Pharmacol 1998;56:405-14.
40. Zijlstra JG, et al. Topoisomerases, new targets in cancer chemotherapy. Med Oncol Tumor Pharmacother 1990;7:11-8.
41. Pommier Y. DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother Pharmacol 1993;32:103-8.
42. Aubel-Sadron G, Londos-Gagliardi D. Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review. Biochimie 1984;66:333-52.
43. Booser DJ, Hortobagyi GN. Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs 1994;47:223-58.
44. Goldman ID, Matherly LH. The cellular pharmacology of methotrexate. Pharmacol Ther 1985;28:77-102.
45. Furst DE. Methotrexate: new mechanisms and old toxicities. Agents Actions Suppl 1993;44:131-7.
46. Huennekens FM. The methotrexate story: a paradigm for development of cancer chemotherapeutic agents. Adv Enzyme Regul 1994; 34:397-419.
47. Reardon JE. Herpes simplex virus type 1 and human DNA polymerase interactions with 2′-deoxyguanosine 5′-triphosphate analogues. Kinetics of incorporation into DNA and induction of inhibition. J Biol Chem 1989;264:19039-44.
48. Kokoris MS, et al. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant. Gene Ther 1999;6:1415-26.
49. Wei SJ, et al. S- and G2-phase cell cycle arrests and apoptosis induced by ganciclovir in murine melanoma cells transduced with herpes simplex virus thymidine kinase. Exp Cell Res 1998;241:66-75.
50. Beltinger C, et al. Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. Proc Natl Acad Sci USA 1999; 96:8699-704.
51. Milross CG, et al. Sequence-dependent antitumor activity of paclitaxel (taxol) and cisplatin in vivo. Int J Cancer 1995;62:599-604.
52. Parker RJ, et al. Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. J Natl Cancer Inst Monogr 1993;15:83-8.
53. Smorenburg CH, et al. Combination chemotherapy of the taxanes and antimetabolites: its use and limitations. Eur J Cancer 2001;37:2310-23.
54. Seidman MA, et al. Variation in adenovirus receptor expression and adenovirus vector-mediated transgene expression at defined stages of the cell cycle. Mol Ther 2001;4:13-21.
55. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004-14.
56. Seidman MA, et al. Enhanced transgene delivery by adenovirus vectors in the presence of paclitaxel: potential mechanic synergy between pharmaceutical and genetic therapies, in American Society of Gene Therapy 2nd Annual Meeting 1999. 1999. Washington DC: American Society of Gene Therapy.
57. Tong X, et al. Adenovirus mediated thymidine kinase gene therapy may enhance sensitivity of ovarian cancer cells to chemotherapeutic agents. Anticancer Res 1998;18:3421-6.
58. Maleniak TC, et al. Adenovirus-mediated expression of HSV1-TK or Fas ligand induces cell death in primary human glioma-derived cell cultures that are resistant to the chemotherapeutic agent CCNU. Cancer Gene Ther 2001;8:589-98.
59. Kramm CM, et al. Synergistic effects of chemotherapeutic treatment and HSV-tk/ganciclovir pharmacogene therapy for Ewing tumors. Molecular Ther 2000;1:S40-41.
60. Cheon J, et al. Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model. Cancer Gene Ther 1997;4:359-65.